US Ex Rel. Alexander Volkhoff v. Janssen Pharmaceutica N.V.

945 F.3d 1237
CourtCourt of Appeals for the Ninth Circuit
DecidedJanuary 2, 2020
Docket18-55643
StatusPublished
Cited by20 cases

This text of 945 F.3d 1237 (US Ex Rel. Alexander Volkhoff v. Janssen Pharmaceutica N.V.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
US Ex Rel. Alexander Volkhoff v. Janssen Pharmaceutica N.V., 945 F.3d 1237 (9th Cir. 2020).

Opinion

FOR PUBLICATION

UNITED STATES COURT OF APPEALS FOR THE NINTH CIRCUIT

UNITED STATES ex rel. ALEXANDER No. 18-55643 VOLKHOFF, LLC, Plaintiff-Appellant, * D.C. No. 2:16-cv-06997- v. RGK-RAO

JANSSEN PHARMACEUTICA N.V.; JANSSEN PHARMACEUTICALS, INC.; OPINION JANSSEN RESEARCH AND DEVELOPMENT, LLC; JOHNSON & JOHNSON; ORTHO-MCNEIL, Defendants-Appellees.

Appeal from the United States District Court for the Central District of California R. Gary Klausner, District Judge, Presiding

Argued and Submitted November 14, 2019 Pasadena, California

Filed January 2, 2020

* The caption’s reference to Alexander Volkhoff, LLC as “Plaintiff- Appellant” reflects the appeal-initiating documents. As we explain herein, Alexander Volkhoff, LLC is neither a plaintiff in this action nor a proper appellant of the district court order at issue on appeal. 2 U.S. EX REL. VOLKHOFF V. JANSSEN PHARMACEUTICA

Before: FERDINAND F. FERNANDEZ, MILAN D. SMITH, JR., and ERIC D. MILLER, Circuit Judges.

Opinion by Judge Milan D. Smith, Jr.

SUMMARY **

Quit Tam / Appellate Jurisdiction

The panel dismissed for lack of jurisdiction Alexander Volkhoff, LLC’s appeal from the dismissal of a first amended qui tam complaint filed by relator Jane Doe pursuant to the False Claims Act and state false claims laws.

The panel held that this court lacks jurisdiction to hear nonparty Volkhoff’s appeal, where Volkhoff, which substituted itself out when Jane Doe filed the first amended complaint, chose not to participate in the district court proceedings; and where Volkhoff failed to show that the equities favor hearing its appeal.

The panel rejected Volkhoff’s argument that this court should infer from the notice of appeal that Jane Doe – a party in the district court proceedings – intended to appeal. The panel wrote that it is not clear from the notice, as required by Fed. R. App. P. 3(c), that Jane Doe intended to appeal. The panel rejected the proposition that Volkhoff, an LLC, is interchangeable with Jane Doe, a natural person; and wrote that the record undermines Volkhoff’s argument that

** This summary constitutes no part of the opinion of the court. It has been prepared by court staff for the convenience of the reader. U.S. EX REL. VOLKHOFF V. JANSSEN PHARMACEUTICA 3

Volkhoff’s failure to name Jane Doe as an appellant was an inadvertent omission.

COUNSEL

C. Brooks Cutter (argued) and John R. Parker, Jr., Cutter Law P.C., Sacramento, California; Audra Ibarra, Law Office of Audra Ibarra, Palo Alto, California; Mychal Wilson, Law Offices of Mychal Wilson, Santa Monica, California; for Plaintiff-Appellant.

Michael A. Schwartz (argued) and Erin Colleran, Pepper Hamilton LLP, Philadelphia, Pennsylvania; Jeffrey M. Goldman, Pepper Hamilton LLP, Los Angeles, California; for Defendants-Appellees.

OPINION

M. SMITH, Circuit Judge:

Alexander Volkhoff, LLC (Volkhoff) appeals the district court’s dismissal of the qui tam complaint filed by relator Jane Doe pursuant to the False Claims Act (FCA), 31 U.S.C. §§ 3729–3733, and analogous state false claims laws. 1 However, Volkhoff was not a party to Jane Doe’s complaint. Moreover, it is not clear from Volkhoff’s notice of appeal (Notice), as required by Federal Rule of Appellate Procedure

1 In a qui tam action brought pursuant to the FCA, a private plaintiff, referred to as a “relator,” initiates a suit on behalf of the government for alleged fraud. See 31 U.S.C. § 3730; United States ex rel. Eisenstein v. City of New York, 556 U.S. 928, 932 (2009). Herein, we use “relator,” except where necessary to indicate that the parties used (or did not use) the term “plaintiff.” 4 U.S. EX REL. VOLKHOFF V. JANSSEN PHARMACEUTICA

3(c), that Jane Doe also sought to take an appeal. Because Volkhoff is a nonparty that cannot appeal, and Jane Doe was not properly named as an appellant, we dismiss this appeal for lack of appellate jurisdiction.

FACTUAL AND PROCEDURAL BACKGROUND

On September 16, 2016, shortly after its incorporation as a Delaware limited liability company, Volkhoff filed a qui tam complaint (the Original Complaint) in federal district court. The Original Complaint named Volkhoff as the relator and alleged violations of the FCA and various states’ false claims laws by Defendants Janssen Pharmaceutica N.V., Janssen Pharmaceuticals, Inc., Janssen Research & Development, LLC, Johnson & Johnson, and Ortho-McNeil (Defendants). In particular, the Original Complaint alleged that Defendants fraudulently and unlawfully marketed their medications. Neither the United States nor any state elected to intervene, allowing Volkhoff to proceed with the Original Complaint. 2

Following Defendants’ motion to dismiss the Original Complaint, Volkhoff did not oppose the motion. Instead, Volkhoff’s counsel filed a First Amended Complaint (FAC). The FAC alleged the same claims as those Volkhoff alleged in the Original Complaint. The FAC, however, removed

2 FCA suits are subject to certain procedural requirements, including the government’s sole right to intervene, generally within 60 days of the suit’s filing. See 31 U.S.C. § 3730; Eisenstein, 556 U.S. at 932. Like the FCA, the state false claims laws invoked by the Original Complaint provide their respective state governments with an opportunity to intervene. See, e.g., Cal. Gov’t Code §§ 12650–12656; Colo. Rev. Stat. §§ 25.5-4-303.5–25.5-4-310. Because we dismiss this appeal for lack of appellate jurisdiction, we do not reach any other procedural issues relating to qui tam suits that are raised on appeal. U.S. EX REL. VOLKHOFF V. JANSSEN PHARMACEUTICA 5

Volkhoff as the relator and named Jane Doe, an anonymous natural person, as the only relator.

The FAC did not mention Volkhoff or its relationship to Jane Doe. In filings before the district court and our court, Jane Doe and Volkhoff acknowledge that the replacement of Volkhoff by Jane Doe was a tactical decision aimed at avoiding the dismissal of the Original Complaint’s FCA employment retaliation claim. The name change responded to Defendants’ first motion to dismiss, which argued that Volkhoff, as a limited liability company, lacked standing to assert an FCA retaliation claim.

Defendants moved to dismiss Jane Doe’s FAC. The district court dismissed the FAC on April 19, 2018. In relevant part, the district court dismissed Jane Doe’s FCA claims for lack of subject matter jurisdiction based on the so- called “first-to-file bar,” which prevents private third parties from intervening in or filing similar FCA qui tam lawsuits after an initial relator has filed one. See 31 U.S.C. 3730(b)(5); United States ex rel. Lujan v. Hughes Aircraft Co., 243 F.3d 1181, 1187 (9th Cir. 2001). In concluding that the first-to-file bar applied, the district court found that Jane Doe was not a party to the Original Complaint that Volkhoff had filed, and that she and Volkhoff were distinct legal persons.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
945 F.3d 1237, Counsel Stack Legal Research, https://law.counselstack.com/opinion/us-ex-rel-alexander-volkhoff-v-janssen-pharmaceutica-nv-ca9-2020.